TBAJ-587-CL-001 is the first Phase 1 trial in humans conducted by TB Alliance through the European Regimen Accelerator for Tuberculosis
TB Alliance has built the largest portfolio of potential new tuberculosis (TB) treatments in history. Since inception, it has introduced
NEW YORK (July 15, 2021)—To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions
TB Alliance’s ZeNix trial in South Africa and Eastern Europe sought to optimize the 6-month treatment regimen with reduced exposure
TB Alliance has shifted the TB treatment research paradigm from a focus on developing individual drugs to one of developing
As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those
TOKYO and NEW YORK (March 31, 2021)—Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and
March 25, 2021 – Results of TB Alliance’s Phase 3 clinical trial, known as STAND, have been published in the International Journal
PRETORIA (24 March 2021)—On World TB Day, as society reflects on how COVID-19 became the world’s most lethal infection in the
NEW YORK (March 23, 2021) – Interested researchers are invited to apply to access the MARK-TB (Markedly Accelerating Research with
